Z-LEHD-fmk Options
MI-CP151 was a period 1b randomised, double-blind, placebo managed, dose-escalation, multicentre examine To judge a number of intravenous doses of sifalimumab, in Grownup sufferers with dermatomyositis or polymyositis (NCT00533091). Main trial aims were To guage the protection and tolerability of sifalimumab in dermatomyositis or polymyositis indiv